Common use of Definitions from Master Collaboration Agreement Clause in Contracts

Definitions from Master Collaboration Agreement. Capitalized terms used herein but not defined, including each of the following terms, have the meaning described in the Master Collaboration Agreement: Defined Term: Antibody Accounting Principles Affiliate Antitrust Law Background IP Bankruptcy Code Business Combination Business Day Calendar Quarter Calendar Year Celgene Indemnitees Celgene Independent Products Celgene IP Celgene Option Exercise Notice Celgene Patents Claims Clinical Trial Co-Development & Co-Commercialization Agreement Collaboration Candidate Collaboration IP Commercialization Commercially Reasonable Efforts Confidential Information Control, Controls or Controlled Cover, Covering or Covered Damages CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Defined Term: Data Package Development Development Candidate Diagnostic Product Dollars or $ EMA Equity Purchase Agreement Executive Officers FDA Field Good Clinical Practices or GCP Good Laboratory Practices or GLP Good Manufacturing Practices or GMP Guiding Principles IIT or Investigator Initiated Trial IND Implementation Date Inventions Joint Collaboration IP Jounce Indemnitees Jounce IP Jounce Patents Jounce Program Jounce Program Assets Know-How Law or Laws Licensed Product Litigation Conditions MAA Manufacture or Manufacturing New Drug Application or NDA Option Option Exercise Notice Patents PD-1 Program Person Phase 3 Clinical Trial Pivotal Clinical Trial Product Liability Products Program Prosecution and Maintenance Regulatory Approval Regulatory Authority Regulatory Materials CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Defined Term: Reimbursable Costs Resulting Patents Specifically Directed Sublicensee Target Territory Third Party Third Party License United States or U.S. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

Definitions from Master Collaboration Agreement. Capitalized terms used herein but not defined, including each of the following terms, have the meaning described in the Master Collaboration Agreement: Defined Term: Antibody Accounting Principles Affiliate Antitrust Law Background IP Bankruptcy Code Biologics License Application or BLA Business Combination Business Day Calendar Quarter Calendar Year CDR Celgene Indemnitees Celgene Independent Products Celgene IP Celgene Option Exercise Notice Celgene Patents Claims Clinical Trial CMC Activities Co-Development & Co Indication Co-Commercialization Agreement Co Product Collaboration Candidate Candidates Collaboration IP Commercialization Commercialization Activities Commercialization Lead Party Commercially Reasonable Efforts Confidential Information Control, Controls or Controlled Cover, Covering or Covered Damages Data Package Development Development & Commercialization Agreement CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Defined Term: Data Package Development Development Candidate Development Lead Party Diagnostic Product Dollars or $ EMA Equity Purchase Agreement Executive Officers FDA Field First Other Program Good Clinical Practices or GCP Good Laboratory Practices or GLP Good Manufacturing Practices or GMP Guiding Principles IIT or Investigator Initiated Trial IND Immune Activator Immune Inhibitor Implementation Date IND Inventions Joint Collaboration IP Jounce Indemnitees Jounce IP Jounce Patents Jounce Program Jounce Program Assets JSC Know-How Law or Laws Licensed Product Litigation Conditions LO Criteria MAA Major Market Countries Manufacture or Manufacturing New Drug Application or NDA Option Option Exercise Notice Patents PD-1 Program Patent Committee Person Phase 3 Clinical Trial Pivotal Clinical Trial Product Liability Products Program Prosecution and Maintenance Regulatory Approval Regulatory Authority Regulatory Lead Party Regulatory Materials Reimbursable Costs CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Defined Term: Reimbursable Costs Resulting Patents ROW Territory Specifically Directed Sublicensee Target Territory Third Party Third Party License United States or U.S. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

Definitions from Master Collaboration Agreement. Capitalized terms used herein but not defined, including each of the following terms, have the meaning described in the Master Collaboration Agreement: Defined Term: Antibody Accounting Principles Affiliate Antitrust Law Background IP Bankruptcy Code BD Acquiring Party BD Evaluation Period BD Opt-In Payment BD Option Exercise Notice Biologics License Application or BLA Business Combination Business Day Calendar Quarter Calendar Year Defined Term: CAR [***] BD Program Celgene Background IP Celgene Co-Promote Program Celgene Indemnitees Celgene Independent Products Celgene IP Celgene Option Exercise Notice Patents Celgene Patents Platform Technology Celgene Program Celgene Program Assets [***] BD Program [***] Program Celgene Upstream Agreements Cellular Therapy Products Claims Clinical Trial CMC Activities Co-Development & Co-Commercialization Agreement Collaboration Candidate Co Product Collaboration IP Commercialization Commercialization Activities Commercialization Lead Party Commercialization Opt-In Right Commercially Reasonable Efforts Confidential Information Control, Controls or Controlled Core Dossier Studies Cover, Covering or Covered Damages CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Defined Term: Data Package ] Development Development & Commercialization Agreement Development Candidate Development Plan Development Lead Party Diagnostic Product Dollars or $ EMA Equity Purchase Agreement Executive Officers FDA Field FTE Rate [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Defined Term: Good Clinical Practices or GCP Good Laboratory Practices or GLP Good Manufacturing Practices or GMP Guiding Principles IIT Xxxxx-Xxxxxx Act [***] Agent or Investigator Initiated Trial [***] In Vivo Product IND Implementation Date Indication Inventions Joint Collaboration IP Jounce JRDC JSC Juno Background IP Juno Indemnitees Jounce IP Jounce Juno Option Exercise Notice Juno Patents Jounce Juno Platform Technology Juno Program Jounce Program Assets Juno Upstream Agreements JRDC Xxxxx-Xxxxxx Act Know-How Law or Laws Licensed Product Litigation Conditions MAA Major EU Market Countries Manufacture or Manufacturing Manufacturing Agreement New Drug Application or NDA North America Territory Offering Party Option Option Exercise Notice Patents PD-1 Program Patent Patent Committee Person Phase 3 Clinical Trial Pivotal Phase 4 Clinical Trial Post Option Costs Products Product Liability Products Program Prosecution and Maintenance [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Defined Term: [***] Regulatory Approval Regulatory Authority Regulatory Lead Party Regulatory Materials CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Defined Term: Reimbursable Costs Resulting Patents Research ROW Territory Small Molecule Compounds Specifically Directed Sublicensee Sublicensees Target Territory Third Party Third Party License United States or U.S. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.] BD Program [***] Program [***] Option Exercise Notice [***] Program United States or U.S.

Definitions from Master Collaboration Agreement. Capitalized terms used herein but not defined, including each Each of the following terms, have terms has the meaning described in the Master Collaboration Agreement: Defined Term: Antibody Term Abraxane® Accounting Principles Affiliate Antibody Construct Antibody Technology Antitrust Law Background IP Bankruptcy Code Biologics License Application or BLA Biomarker Bispecific Technology BSP BSP Option Term BSP Program Business Combination [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Business Day Calendar Quarter Calendar Year Celgene Background IP Celgene Background IP Transfer Agreement Celgene Background Patents Celgene Indemnitees Celgene Independent Products Celgene IP Celgene Option Exercise Notice Owned Inventions Celgene Patents CMC Activities Claims Clinical Trial Co-Development & Co Candidate Co-Commercialization Agreement Co Product Collaboration Candidate Collaboration IP Collaboration Patents Commercialization Commercially Reasonable Efforts Confidential Information Control, Controls or Controlled Cover, Covering or Covered Damages CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Defined Term: Data Package DEM Option Term DEM Program Demcizumab Development Development Candidate & Commercialization Agreement Diagnostic Product Different Histology DLL4 Dollars or $ EMA Equity Purchase Agreement Excluded MorphoSys Antibodies Excluded Target Executive Officers Existing Agreements FDA Field FPFV Good Clinical Practices or GCP Good Laboratory Practices or GLP Good Manufacturing Practices or GMP Guiding Principles IIT or Investigator Initiated Trial Governmental Authority [***] Designated Program [***] Designation Notice [***] Option Term [***]SM Agreement [***]SM Program Asset [***]SM Program Compound IND Implementation Date Indication Inventions Joint Collaboration IP Jounce Indemnitees Jounce IP Jounce Patents Jounce Program Jounce Program Assets JSC Know-How Law or Laws Licensed Candidate Licensed Product Litigation Conditions MAA Xxxxx Xxxxx Agreements Lonza Collaboration Agreement Lonza Multi-Product License Agreement Lonza Research Agreement MAbTrap Technology Major EU Market Manufacture or Manufacturing New Drug Application or NDA MHLW Michigan Agreement Michigan Patents MorphoSys Agreement Non-RSPO3 Designated Program OncoMed Indemnitees OncoMed IP OncoMed Patents OncoMed Platform Technology Option Option Exercise Notice Patents PD-1 Term Patent Patent Committee Pathway Designated Program Person Phase 3 Clinical Trial Pivotal Clinical Trial Product Product Candidate Product Liability Products Program [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Prosecution and Maintenance Protein Therapeutic Regulatory Approval Regulatory Authority Regulatory Materials CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Defined Term: Reimbursable Costs Resulting Patents RSPO3 Designated Program RSPO Designated Program RSPO Designation Notice RSPO Option Term Specifically Directed Sublicensee Target Territory Third Party Third Party License United States or U.S. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.University of Michigan Valid Claim VEGF